Liver/Biliary Disorders News

PHILADELPHIA — Iqirvo demonstrated significant biochemical response and alkaline phosphatase normalization in patients with both early- and advanced-stage primary biliary cholangitis, according to late-breaking data presented here.

PHILADELPHIA — Patients with cirrhosis had an increased risk for bleeding within 30 days of colorectal endoscopic mucosal resection compared with controls, although the need for reintervention or ICU admission was similar between groups.

PHILADELPHIA — Hepatologists and gastroenterologists must be internal medicine physicians, not just specialists, to determine the root cause of complaints in patients with suspected hepatic encephalopathy, according to an expert.

PHILADELPHIA — Rifaximin monotherapy reduced episode recurrence and “may confer” a survival benefit compared with lactulose monotherapy among patients with cirrhosis and a history of overt hepatic encephalopathy, according to a presenter.

PHILADELPHIA — The rate of alcohol-associated liver disease among women is the rise and physicians must keep it in mind when discussing medical history with their female patients, according to a review presented here.

PHILADELPHIA — Primary sclerosing cholangitis is an independent risk factor for colorectal cancer, with an “almost three-times higher” risk among patients without inflammatory bowel disease vs. the general population, a researcher reported.

A diagnostic tool based on speech variables helped identify minimal hepatic encephalopathy and may predict time to development of overt hepatic encephalopathy in patients with cirrhosis, according to a study published in Hepatology.

Rates of liver-related mortality increased by 19.1% from 2018 to 2021 and varied “several-fold” between states, underscoring the need for improved access to liver transplantation regardless of location, according to researchers.

Patients who tested positive for hepatitis D virus antibodies were at greater risk for developing hepatocellular carcinoma and other adverse liver-related outcomes, often at a young age, according to study results.

Patients treated with denifanstat 50 mg vs. placebo achieved significant improvements in metabolic dysfunction-associated steatohepatitis resolution and fibrosis, according to study results in The Lancet Gastroenterology & Hepatology.